Class 424/247.1 - Clostridium (e.g., Clostridium tetani, Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium chauvoei, etc.)

Subclass of Class 424 - Drug, bio-affecting and body treating compositions
Definition: Subject matter wherein the bacterium is of the genus Clostridium.
No. of applications: 40
Last issue date: 01/19/2012

Application No.	Application Title	Issue Date
20120014993	CLOSTRIDIUM TAENIOSPORUM SPORES AND SPORE APPENDAGES AS SURFACE DISPLAY HOSTS, DRUG DELIVERY DEVICES, AND NANOBIOTECHNOLOGICAL STRUCTURES The present disclosure relates to spore surface display compositions comprising a spore having at least one nucleic acid sequence encoding for at least one polypeptide and operable to express the polypeptide on a surface of the spore. In some embodiments, the displayed ...	01/19/2012
20120003277	NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the sam...	01/05/2012
20110311589	COMPOSITIONS AND DOSAGE REGIMES COMPRISING A CLOSTRIDIAL VACCINE AND LEVAMISOLE A composition and dosage regime including a vaccine and levamisole for the treatment of clostridial diseases and helminthiasis. New methods of administration relating to particular dosage regimes of such a composition are also claimed....	12/22/2011
20110293723	SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta...	12/01/2011
20110268765	Injectable Botulinum Toxin Formulations This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages o...	11/03/2011
20110182847	USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxi...	07/28/2011
20110150931	RAPID RESPONSES TO DELAYED BOOSTER IMMUNISATIONS Booster immunization can lead to rapid induction of protective immunity against pathogens (e.g. ≦7 days after the booster dose). This rapid response means that booster immunization can be used at short notice prior to an event that might require an activated immune re...	06/23/2011
20110142881	TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular ...	06/16/2011
20110135685	Edible Vaccines Expressed in Soybeans The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer an...	06/09/2011
20110135679	COMPOSITIONS FOR INDUCING IMMUNE RESPONSES The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a...	06/09/2011
20110104061	TREATMENT OF RENAL HYPERTENSION OR CAROTID SINUS SYNDROME WITH ADVENTITIAL PHARMACEUTICAL SYMPATHETIC DENERVATION OR NEUROMODULATION Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be t...	05/05/2011
20110076305	EXTRACELLULAR MATRIX MATERIALS AS VACCINE ADJUVANTS FOR DISEASES ASSOCIATED WITH INFECTIOUS PATHOGENS OR TOXINS Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuv...	03/31/2011
20100330125	NOVEL POLYSACCHARIDE IMMUNOGENS FROM CLOSTRIDIUM DIFFICILE The application relates to Clostridium difficile cell surface polysaccharides, compositions comprising Clostridium difficile cell surface polysaccharides, and includes kits, methods and uses thereof....	12/30/2010
20100291152	CHEMICALLY MODIFIED PEPTIDES WITH IMPROVED IMMUNOGENICITY The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides compositions comprising an antigenic peptide, wherein the peptide has been treated...	11/18/2010
20100291131	CLOSTRIDIAL TOXIN NETB The present invention relates to a polypeptide based toxin that originates from Clostridium perfringens. The invention further relates to immunogenic compositions comprising the toxin and methods to vaccinate animals, for example chickens, such that they are less...	11/18/2010
20100285064	ADJUVANT COMPOSITION FOR VACCINE The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant....	11/11/2010
20100266534	Human Lymphocyte Vaccine Adjuvant The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent...	10/21/2010
20100266632	VACCINE COMPOSITION COMPRISING AN IMMUNOADJUVANT COMPOUND CONSISTING OF A RHO GTPASE FAMILY ACTIVATOR An immunogenic or vaccine composition comprising an immunoadjuvant compound consisting of a Rho GTPase activator. The Activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to ...	10/21/2010
20100255022	VACCINE AGAINST CLOSTRIDIUM PERFRINGENS There is provided a vaccine for controlling Clostridium perfringens in animals, and particularly necrotic enteritis in poultry. The vaccine may comprise a C. perfringens antigenic polypeptide or variant thereof, a nucleic acid encoding the C. perfringen...	10/07/2010
20100247573	Stabilization of Vaccines by Lyophilization This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions....	09/30/2010
20100247537	ADJUVANT COMBINATIONS OF NKT ACTIVATOR, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is als...	09/30/2010
20100215679	METHODS AND COMPOSITIONS FOR TREATING TULAREMIA The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach...	08/26/2010
20100196423	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally activ...	08/05/2010
20100166800	RECOMBINANT ATTENUATED CLOSTRIDIUM ORGANISMS AND VACCINE The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens...	07/01/2010
20100158952	MICROORGANISMS OR FRACTIONS THEREOF CAPABLE OF ACTIVATING CELLULAR IMMUNITY AGAINST CARBOHYDRATES The present invention relates to the field of prevention and treatment of tumors and gastrointestinal disorders. The present invention relates to the prevention and treatment of Core-1-positive carcinomas. The invention relates to coreotics and a method of producing the...	06/24/2010
20100119554	TRANSPLANTS The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and/o...	05/13/2010
20100112078	POLYMER PARTICLES BASED VACCINE The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wher...	05/06/2010
20100062025	Use of Clostridium perfringens type C bacterium for the manufacture of a vaccine The present invention relates to the use of a vaccine comprising Clostridium perfringens type C bacterium for protecting swine against Clostridium perfringens type A infection....	03/11/2010
20100028448	IMMUNOGENIC COMPOSITIONS AND METHODS OF USE Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprisin...	02/04/2010
20100021546	CONTROLLED-RELEASE IMMUNOGENIC FORMULATIONS TO MODULATE IMMUNE RESPONSE Single-dose controlled-release immunogenic formulations, such as vaccines, based on bioerodible polyanhydride copolymer or homopolymer microparticles for the control of immune response mechanisms are provided. The copolymer or homopolymer microparticles degrade by surfa...	01/28/2010
20090297559	USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pu...	12/03/2009
20090214466	Methods of Alleviating Disorders and Their Associated Pain The invention relates generally to the field of treatment of headache, post-laminectomy syndrome, and other disorders associated with localized pain. The compositions and methods described herein are useful for alleviating both the disorders and the pain associated ther...	08/27/2009
20090214537	Serum Resistance Factors of Gram Positive Bacteria A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection....	08/27/2009
20090181054	Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conju...	07/16/2009
20090169636	Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide and an immunological species selected from an antigen, an immunological adju...	07/02/2009
20090136623	GROWTH INHIBITORY COMPOSITION AGAINST PATHOGENIC BACTERIA OF MEAT BASED FOOD STUFF COMPRISING IGY The present invention relates to growth-inhibitory composition against pathogenic bacteria of meat based food stuff comprising IgY, a specific immunoglobulin derived from yolk of egg. The 12 representative bacteria and other microbes deteriorating quality of process mea...	05/28/2009
20090110699	Antigen-Adjuvant Compositions and Methods Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine com...	04/30/2009
20090092639	IMMUNOGENIC COMPOSITION Methods and compositions for increasing antibody titer in egg yolks and for using the antibodies are disclosed....	04/09/2009
20090010964	Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered w...	01/08/2009
20080213316	Destruction of spores through glycoconjugate enhanced phagocytosis Methods for enhancing destruction and killing of bacterial spores via phagocytosis, where phagocytosis of bacterial spores is enhanced by using a glycoconjugate. In one embodiment, the method includes the steps of modifying a surface of a bacterial spore to increase adh...	09/04/2008

PatentStorm

Bizarre Patents

PatentStorm News

Class 424/247.1 - Clostridium (e.g., Clostridium tetani, Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium chauvoei, etc.)